Boussard & Gavaudan Investment Management LLP Sage Therapeutics, Inc. Transaction History
Boussard & Gavaudan Investment Management LLP
- $121 Million
- Q1 2025
A detailed history of Boussard & Gavaudan Investment Management LLP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Boussard & Gavaudan Investment Management LLP holds 655,662 shares of SAGE stock, worth $4.46 Million. This represents 4.32% of its overall portfolio holdings.
Number of Shares
655,662Holding current value
$4.46 Million% of portfolio
4.32%Shares
1 transactions
Others Institutions Holding SAGE
# of Institutions
217Shares Held
49.9MCall Options Held
220KPut Options Held
312K-
Black Rock Inc. New York, NY5.22MShares$35.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$34.5 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$30.4 Million4.6% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$18.6 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$14.2 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $404M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...